Feasibility of ASL - based phMRI with a single dose of oral
citalopram for repeated assessment of serotonin function
Not exact matches
«Vortioxetine in depression: No hint of added benefit: Inadequate limitation of the study pool
for the indirect comparison with
citalopram.»
It compared moderate and severe episodes,
for which the G - BA had specified an SSRI and an SSRI plus offer of psychotherapy as appropriate comparator therapy, with the drug
citalopram without considering psychotherapy.
I ultimately came to rely on three medications
for my mental health:
citalopram (Celexa), lamotrigine (Lamictal) and aripiprazole (Abilify).
She said that substitutes are available
for some anticholinergic drugs, including a selective serotonin re-uptake inhibitor (SSRI) antidepressant like
citalopram (Celexa) or fluoxitene (Prozac)
for depression, or a second - generation antihistamine such as loratadine (Claritin)
for allergy relief.
66 patients with major depressive disorder accompanied by anxious distress were randomly assigned to receive either saffron (30 mg / day) or
citalopram (40 mg / day)
for 6 weeks.
This was so, first, because Lundbeck's process patents did not constitute insurmountable barriers
for the generic undertakings, which were willing and ready to enter the
citalopram market, and which had already made considerable investments to that end (para 124).
This is not only because the agreements provided simultaneously
for the limitation of generic market entry and
for significant value transfers, but is also due to some further aggravating factors: the payments amounted to the expected profits of the generics had they entered the market; the real purpose was not to resolve the underlying patent dispute between the parties insofar as the agreements did not provide
for market entry upon their expiration; and the content of the agreements went beyond the scope of Lundbeck's patents, since they were intended to prevent the sales of all types of generic
citalopram while Lundbeck could not have obtained the same outcome through the enforcement of its patents.
Lundbeck's compound patent
for citalopram had expired by January 2002 in most EEA countries, but the company held certain process patents which did not constitute insurmountable barriers to entry
for generic producers.
For the first time the EC imposed substantial fines against the brand name Lundbeck (over $ US 100 million) and 4 generic manufacturers (totalling over $ US 65 million) for entering into a reverse payment agreement regarding the «blockbuster» antidepressant citalopr
For the first time the EC imposed substantial fines against the brand name Lundbeck (over $ US 100 million) and 4 generic manufacturers (totalling over $ US 65 million)
for entering into a reverse payment agreement regarding the «blockbuster» antidepressant citalopr
for entering into a reverse payment agreement regarding the «blockbuster» antidepressant
citalopram.
We appreciate the support of Forest Laboratories
for providing
citalopram at no cost.